<SEC-DOCUMENT>0001178913-24-003886.txt : 20241202
<SEC-HEADER>0001178913-24-003886.hdr.sgml : 20241202
<ACCEPTANCE-DATETIME>20241202070347
ACCESSION NUMBER:		0001178913-24-003886
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20241202
FILED AS OF DATE:		20241202
DATE AS OF CHANGE:		20241202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		241517395

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2432417.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: zk-global
         Document created using Broadridge PROfile 24.9.1.5252
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><br>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">&#160;<font style="font-size: 14pt;">UNITED
          STATES&#160;</font></font><font style="font-size: 14pt; font-family: 'Times New Roman',Times,serif;">&#160;&#160;</font></div>
    <div style="line-height: 1.25; font-size: 14pt;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C.&#160;20549</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-size: 14pt;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">FORM 6-K</div>
    </div>
    <div style="text-align: center; line-height: 1.25;">&#160;&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Report of Foreign Private Issuer</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">of&#160;the Securities Exchange Act of 1934</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">For the month of December 2024<br>
      Commission File No.:001-35773</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-size: 16pt;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">REDHILL BIOPHARMA LTD.</div>
    </div>
    <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">21 Ha'arba'a Street, Tel Aviv, 6473921, Israel</div>
    <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 28.35pt; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form
      40-F.&#160;&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Form 20-F&#160;&#9746;&#160;&#160; &#160;&#160; &#160; Form 40-F&#160;&#9744;</div>
    <div style="text-indent: 14.2pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Attached hereto and incorporated by reference herein is a press release issued by the Registrant entitled: &#8220;RedHill Biopharma Awarded
      Judgment of Approximately $8 Million Plus Costs by New York Supreme Court&#8221;.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and
      Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No.
      333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001) and on June 20, 2024 (File No.
      333-280327), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on
      August 9, 2024 (File No. 333-281417).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURES</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Pursuant to the requirements of&#160;the&#160;Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
      by the undersigned, thereunto duly authorized.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zfb3ab769a483409d8d845f254a09eeeb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">REDHILL BIOPHARMA LTD.</div>
          </td>
          <td style="width: 18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top;" colspan="2">
            <div style="line-height: 1.25;">(the "Registrant")</div>
          </td>
          <td style="width: 18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 27.77%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Date: December 2, 2024</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td nowrap="nowrap" style="width: 27.77%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Dror Ben-Asher</div>
          </td>
          <td style="width: 18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">Name:</div>
          </td>
          <td nowrap="nowrap" style="width: 27.77%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Dror Ben-Asher</div>
          </td>
          <td style="width: 18%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">Title:</div>
          </td>
          <td style="width: 27.77%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Executive Officer</div>
          </td>
          <td style="width: 18%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
  </div>
  <br>
  <div>
    <div style="line-height: 1.25;">
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div class="BRPFPageFooter">
        <div style="line-height: 1.25;">
          <div style="line-height: 1.25;"><img src="image00002.jpg">
            <div><br>
            </div>
            <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">

                <tr>
                  <td style="border-width: 4px 2px 2px; border-style: solid; border-color: rgb(0, 0, 0); width: 100%;">
                    <div style="text-align: center; text-indent: 42.55pt; margin-right: 0.75pt; margin-left: 0.75pt; line-height: 1.25;"><br>
                    </div>
                    <div style="text-align: center; line-height: 1.25; font-size: 16pt; font-weight: bold;">Press Release</div>
                    <div style="text-align: center; text-indent: 42.55pt; margin-right: 0.75pt; margin-left: 0.75pt; line-height: 1.25;"><br>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;"><br>
          </div>
          <div style="line-height: 1.25;">
            <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"><u>RedHill Biopharma Awarded Judgment of Approximately </u></div>
            <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;"><u>$8 Million Plus Costs by New York Supreme Court</u></div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">RedHill has been awarded a judgment of approximately $8 million plus costs in a summary </div>
            <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. Ltd</div>
            <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">--</div>
            <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">The Court dismissed the entirety of Kukbo&#8217;s counterclaims, ruling in favor of RedHill&#8217;s </div>
            <div style="text-align: center; margin-left: 18pt; line-height: 1.25; font-style: italic;">demonstrated good faith commitment to the spirit and the letter of the agreements</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">TEL-AVIV, Israel / RALEIGH, NC,
                December 2, 2024 /PRNewswire/ -- </font>RedHill Biopharma Ltd. (Nasdaq: RDHL) (&#8220;RedHill&#8221; or the &#8220;Company&#8221;), a specialty biopharmaceutical company, today announced that the Company has been awarded approximately $8 million (consisting of
              $6.5 million plus interest amounting to approximately $1.5 million), plus costs in a summary judgment by the Supreme Court of the State of New York, New York County (the &#8220;Court&#8221;), in its legal proceedings (Index number: 653200/2022) against
              Kukbo Co. Ltd. (&#8220;Kukbo&#8221;), domiciled in South Korea.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25;">The case refers to Kukbo&#8217;s failure to make agreed payments to RedHill, pursuant to a Subscription Agreement (the &#8220;SA&#8221;), dated
              October 25, 2021, and a subsequent Exclusive License Agreement (the &#8220;ELA&#8221; and together with the SA, the &#8220;Agreements&#8221;), dated March 14, 2022, entered into by the two companies.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">Dror Ben-Asher, RedHill&#8217;s CEO:</font>
              &#8220;RedHill thanks the Court for this crystal-clear judgment, affirming the Company&#8217;s just position from the beginning of the relationship, and in making correct provision for full reparation for the contractual breaches. The Company is also
              grateful to Haynes and Boone, LLP for their expert counsel and legal representation in this case.&#8221;</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25;">Upon entry, Kukbo has a right to seek an appeal of the judgment, which may or may not be granted.&#160; RedHill intends to pursue its
              attorneys&#8217; fees and collection of the judgment.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About RedHill Biopharma&#160;&#160;</div>
            <div style="text-align: justify; line-height: 1.25;">RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S commercialization and
              development of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the gastrointestinal drug <font style="font-weight: bold;">Talicia</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><font style="font-weight: bold;">,</font> for the treatment of <font style="font-style: italic;">Helicobacter pylori (H. pylori)</font> infection in adults<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>. RedHill&#8217;s key clinical late-stage development programs include: (i)&#160;<font style="font-weight: bold;">opaganib (ABC294640)</font>, ), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, , targeting multiple indications with a
              U.S. government collaboration for development for Acute Radiation Syndrome (ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 program in oncology; (ii)&#160;<font style="font-weight: bold;">RHB-107&#160;</font>(<font style="font-weight: bold;">upamostat</font>), an oral broad-acting, host-directed, serine protease inhibitor with potential for
              pandemic preparedness is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19, with non-dilutive external funding covering the entirety of the RHB-107 arm of the 300-patient Phase 2 adaptive platform trial, and
              is also targeting multiple other cancer and inflammatory gastrointestinal diseases; (iii)&#160;<font style="font-weight: bold;">RHB-102</font>, with potential UK submission for
              chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (iv)&#160;<font style="font-weight: bold;">RHB-104</font>, with positive results from a first Phase 3 study for Crohn's disease; and (v)&#160;<font style="font-weight: bold;">RHB-204</font>,&#160;a Phase 3-stage program for pulmonary nontuberculous mycobacteria (NTM) disease.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; line-height: 1.25;">More information about the Company is available at
              <u>www.redhillbio.com</u> / <u>X.com/RedHillBio</u>.</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
            </div>
            <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Forward-Looking Statements</div>
            <div style="text-align: justify; line-height: 1.25; font-style: italic;">This press release contains "forward-looking statements" within the meaning of the Private Securities
              Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects,"
              "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and include, among others, statements regarding the legal process going forward including Kukbo&#8217;s rights to appeal. Forward-looking
              statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company&#8217;s control and cannot be predicted or quantified, and consequently, actual results may
              differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the risk that the Court&#8217;s ruling will not be upheld in any subsequent
              appeal or that the provisions for reparation for the contractual breaches will not be honored; the Company's ability to maintain compliance with the Nasdaq Capital Market's listing requirements; the risk that the addition of new revenue
              generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the
              risk that the FDA does not agree with the Company's proposed development plans for opaganib for any indication; the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that
              the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful
              in obtaining alternative non-dilutive development funding for RHB-107; the risk that RHB-107's late-stage development for non-hospitalized COVID-19 will not benefit from the resources redirected from the terminated RHB-204 Phase 3 study, and
              that the Phase 2/3 COVID-19 study for RHB-107 may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional
              COVID-19 studies for opaganib and RHB-107 are likely to be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and
              results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or
              develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for
              the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory
              filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia&#174;; (v) the Company's ability to successfully commercialize and promote
              Talicia&#174; and Aemcolo&#174;; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own
              marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies
              or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property
              rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their
              obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the
              Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company
              and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC
              on April 8, 2024. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result
              of new information, future events or otherwise, unless required by law.</div>
            <div style="text-align: justify; line-height: 1.25; font-style: italic;"> <br>
            </div>
            <table cellspacing="0" cellpadding="0" id="z95490f1d085240f7bb0638bcc6f79795" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 53.44%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">Company contact:</div>
                    <div style="line-height: 1.25;">Adi Frish</div>
                    <div style="line-height: 1.25;">Chief Corporate &amp; Business Development Officer</div>
                    <div style="line-height: 1.25;">RedHill Biopharma</div>
                    <div style="line-height: 1.25;">+972-54-6543-112</div>
                    <div style="line-height: 1.25;"><u>adi@redhillbio.com</u></div>
                  </td>
                  <td style="width: 46.56%; vertical-align: top;">&#160;</td>
                </tr>

            </table>
            <div style="line-height: 1.25;">Category: Corporate</div>
            <br>
            <hr noshade="noshade" align="left" style="background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
            <div style="line-height: 1.25;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> Talicia&#174; (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in
              adults. For full prescribing information see: www.Talicia.com.</div>
            <div style="line-height: 1.25;"> <br>
            </div>
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font> </div>
            <div style="line-height: 1.25;">
              <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !, )4# 2(  A$! Q$!_\0
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M9!S79>*O!_C+QYHMW8>);O2=-M?*<PVE@TCB:?:?+:61@#L5L-M4<D5K^(/
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EOK-([69'B922  6&!\P]QQ77XHVB@!%)*@D8R,XZT4N** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
